Jasper Therapeutics (JSPR) Competitors $3.02 -0.02 (-0.66%) Closing price 04:00 PM EasternExtended Trading$2.96 -0.06 (-1.82%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. AQST, PRTA, TERN, PRME, HUMA, SNDL, HRTX, AURA, ALT, and CTORShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Aquestive Therapeutics (AQST), Prothena (PRTA), Terns Pharmaceuticals (TERN), Prime Medicine (PRME), Humacyte (HUMA), SNDL (SNDL), Heron Therapeutics (HRTX), Aura Biosciences (AURA), Altimmune (ALT), and Citius Oncology (CTOR). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Its Competitors Aquestive Therapeutics Prothena Terns Pharmaceuticals Prime Medicine Humacyte SNDL Heron Therapeutics Aura Biosciences Altimmune Citius Oncology Aquestive Therapeutics (NASDAQ:AQST) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership. Which has higher earnings & valuation, AQST or JSPR? Aquestive Therapeutics has higher revenue and earnings than Jasper Therapeutics. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquestive Therapeutics$57.56M6.35-$44.14M-$0.59-6.24Jasper TherapeuticsN/AN/A-$71.27M-$5.24-0.58 Does the media refer more to AQST or JSPR? In the previous week, Jasper Therapeutics had 7 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 15 mentions for Jasper Therapeutics and 8 mentions for Aquestive Therapeutics. Aquestive Therapeutics' average media sentiment score of 0.39 beat Jasper Therapeutics' score of -0.62 indicating that Aquestive Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aquestive Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Jasper Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Negative Do institutionals & insiders believe in AQST or JSPR? 32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 4.6% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts rate AQST or JSPR? Aquestive Therapeutics presently has a consensus target price of $10.14, indicating a potential upside of 175.62%. Jasper Therapeutics has a consensus target price of $29.75, indicating a potential upside of 885.10%. Given Jasper Therapeutics' higher probable upside, analysts clearly believe Jasper Therapeutics is more favorable than Aquestive Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquestive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Jasper Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more risk and volatility, AQST or JSPR? Aquestive Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Is AQST or JSPR more profitable? Jasper Therapeutics has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -100.02%. Aquestive Therapeutics' return on equity of 0.00% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aquestive Therapeutics-100.02% N/A -50.31% Jasper Therapeutics N/A -109.45%-89.82% SummaryAquestive Therapeutics beats Jasper Therapeutics on 9 of the 15 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$45.67M$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-0.5820.8027.0020.10Price / SalesN/A286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book0.737.487.985.56Net Income-$71.27M-$55.04M$3.16B$248.40M7 Day Performance-47.39%5.44%3.69%6.04%1 Month Performance-49.75%2.38%2.91%7.69%1 Year Performance-85.70%5.53%34.30%20.97% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics3.2926 of 5 stars$3.02-0.7%$29.75+885.1%-85.6%$45.67MN/A-0.5820Trending NewsAnalyst ForecastGap UpHigh Trading VolumeAQSTAquestive Therapeutics1.2383 of 5 stars$3.31+1.8%$10.14+206.4%+49.2%$328.78M$57.56M-5.61160PRTAProthena3.0398 of 5 stars$6.07-0.2%$31.50+418.9%-69.0%$326.75M$135.16M-2.92130TERNTerns Pharmaceuticals3.7044 of 5 stars$3.73-2.6%$15.63+318.9%-41.3%$325.78MN/A-3.4240PRMEPrime Medicine4.0479 of 5 stars$2.47+2.1%$10.08+308.2%-27.5%$324.30M$3.85M-1.20234News CoverageOptions VolumeHigh Trading VolumeHUMAHumacyte2.7386 of 5 stars$2.09-1.4%$11.71+460.5%-59.0%$324.20M$1.57M-3.03150News CoverageGap UpSNDLSNDL3.5078 of 5 stars$1.21-1.6%$3.63+199.6%-36.1%$317.96M$671.81M-4.172,516News CoveragePositive NewsHRTXHeron Therapeutics3.9253 of 5 stars$2.07-3.3%$5.00+141.5%-25.1%$315.80M$144.29M-34.50300AURAAura Biosciences1.8805 of 5 stars$6.26-0.3%$22.00+251.4%-12.1%$314.69MN/A-3.2950ALTAltimmune2.1994 of 5 stars$3.87+10.6%$19.00+391.0%-33.1%$313.90M$20K-3.0750Gap DownHigh Trading VolumeCTORCitius Oncology0.3981 of 5 stars$4.35-3.3%$3.00-31.0%N/A$311.24MN/A0.00N/A Related Companies and Tools Related Companies Aquestive Therapeutics Alternatives Prothena Alternatives Terns Pharmaceuticals Alternatives Prime Medicine Alternatives Humacyte Alternatives SNDL Alternatives Heron Therapeutics Alternatives Aura Biosciences Alternatives Altimmune Alternatives Citius Oncology Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free JSPR Stock Alerts